

Sabine C Linn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/258637/publications.pdf>

Version: 2024-02-01

116
papers

4,503
citations

117619

34
h-index

114455

63
g-index

118
all docs

118
docs citations

118
times ranked

5590
citing authors

#	ARTICLE	IF	CITATIONS
1	10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. <i>Lancet Oncology</i> , The, 2016, 17, 1158-1170.	10.7	301
2	Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). <i>Lancet Oncology</i> , The, 2007, 8, 1079-1087.	10.7	268
3	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â€™298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	13.7	260
4	The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 655-661.	2.5	242
5	Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1630-1640.	10.7	237
6	A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. <i>International Journal of Cancer</i> , 2013, 133, 929-936.	5.1	192
7	Validation of 70-gene prognosis signature in node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 483-495.	2.5	154
8	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. <i>Annals of Oncology</i> , 2011, 22, 1561-1570.	1.2	150
9	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1502-1511.	10.7	119
10	MammaPrint Molecular Diagnostics on Formalin-Fixed, Paraffin-Embedded Tissue. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 190-197.	2.8	90
11	PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer. <i>Clinical Pharmacokinetics</i> , 2018, 57, 427-437.	3.5	87
12	Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. <i>Breast Cancer Research</i> , 2014, 16, R47.	5.0	86
13	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. <i>Breast Cancer Research</i> , 2019, 21, 90.	5.0	81
14	Impact of mammographic screening on the detection of good and poor prognosis breast cancers. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 725-734.	2.5	76
15	Safety of trastuzumab emtansine (T-DM1)â€™in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. <i>European Journal of Cancer</i> , 2019, 109, 92-102.	2.8	73
16	Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients â€™ A phase II trial. <i>European Journal of Cancer</i> , 2014, 50, 2190-2200.	2.8	67
17	The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07). <i>BMC Cancer</i> , 2015, 15, 610.	2.6	65
18	DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. <i>Npj Breast Cancer</i> , 2017, 3, 31.	5.2	64

#	ARTICLE	IF	CITATIONS
19	Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 529-541.	27.6	63
20	Clinical relevance of the triple-negative breast cancer concept: Genetic basis and clinical utility of the concept. <i>European Journal of Cancer</i> , 2009, 45, 11-26.	2.8	60
21	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 223-245.	5.4	59
22	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. <i>Breast Cancer Research</i> , 2017, 19, 99.	5.0	58
23	Equivalence of MammaPrint array types in clinical trials and diagnostics. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 279-287.	2.5	57
24	The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment. <i>Annals of Oncology</i> , 2010, 21, 40-47.	1.2	56
25	Estrogen Receptor- β Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1725-1729.	6.3	55
26	Phosphorylation of the oestrogen receptor β at serine 305 and prediction of tamoxifen resistance in breast cancer. <i>Journal of Pathology</i> , 2009, 217, 372-379.	4.5	54
27	PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. <i>Breast Cancer Research</i> , 2014, 16, R13.	5.0	54
28	BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. <i>Molecular Oncology</i> , 2015, 9, 1528-1538.	4.6	54
29	Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. <i>Breast Cancer Research</i> , 2014, 16, R6.	5.0	46
30	High <i>XIST</i> and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a <i>BRCA1</i> -like Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 190-198.	4.1	46
31	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	1.6	45
32	Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 477-483.	2.5	40
33	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	10.9	39
34	Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 793-798.	2.5	38
35	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. <i>European Journal of Cancer</i> , 2017, 78, 37-44.	2.8	38
36	Metabolic Imaging Detects Resistance to PI3K β Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 516-533.e9.	16.8	38

#	ARTICLE	IF	CITATIONS
37	Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 763-770.	7.0	34
38	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. <i>International Journal of Cancer</i> , 2021, 148, 2289-2303.	5.1	34
39	Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. <i>Breast</i> , 2016, 29, 153-159.	2.2	31
40	Prognostic Value of MammaPrint [®] in Invasive Lobular Breast Cancer. <i>Biomarker Insights</i> , 2016, 11, BMI.S38435.	2.5	31
41	4€protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. <i>Molecular Oncology</i> , 2016, 10, 24-39.	4.6	31
42	Impact of 70-Gene Signature Use on Adjuvant Chemotherapy Decisions in Patients With Estrogen Receptor-Positive Early Breast Cancer: Results of a Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2814-2819.	1.6	31
43	Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ER± in Tamoxifen-Associated Endometrial Carcinomas. <i>Cancer Research</i> , 2016, 76, 3773-3784.	0.9	30
44	Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms. <i>Molecular Oncology</i> , 2015, 9, 1274-1286.	4.6	29
45	The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 361-371.	2.5	26
46	Estrogen receptor ± yields treatment-specific enhancers between morphologically similar endometrial tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E1316-E1325.	7.1	25
47	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. <i>BMC Cancer</i> , 2015, 15, 588.	2.6	24
48	PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy. <i>International Journal of Cancer</i> , 2014, 135, 1257-1263.	5.1	23
49	Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 697-705.	2.5	22
50	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 649-655.	2.5	21
51	Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. <i>European Journal of Cancer</i> , 2017, 74, 47-54.	2.8	21
52	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. <i>European Journal of Cancer</i> , 2020, 127, 240-250.	2.8	21
53	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab010.	2.9	21
54	Adjuvant chemotherapy in small node-negative triple-negative breast cancer. <i>European Journal of Cancer</i> , 2020, 135, 66-74.	2.8	20

#	ARTICLE	IF	CITATIONS
55	Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. <i>Annals of Oncology</i> , 2011, 22, 2021-2030.	1.2	19
56	Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	19
57	<sc>FOXA</sc>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. <i>Molecular Oncology</i> , 2018, 12, 1884-1894.	4.6	19
58	Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in <i>de novo</i> stage IV breast cancer patients: study protocol of the i-GO study. <i>BMJ Open</i> , 2020, 10, e040162.	1.9	19
59	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, 241-244.	2.4	18
60	IGF1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 2348-2359.	5.1	18
61	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	7.1	17
62	<i>BRCA1</i>-like profile predicts benefit of tandem high dose epirubicin-cyclophosphamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial. <i>International Journal of Cancer</i> , 2016, 139, 882-889.	5.1	16
63	Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences. <i>British Journal of Cancer</i> , 2018, 119, 832-839.	6.4	15
64	MammaPrint and Blueprint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 808-823.	2.8	15
65	Effect of <sc>HIPEC</sc> according to <sc>HRD</sc>/<sc><i>BRCA</i>wt</sc> genomic profile in stage <sc>III</sc> ovarian cancer: Results from the phase <sc>III</sc> OVHIPEC</sc> trial. <i>International Journal of Cancer</i> , 2022, 151, 1394-1404.	5.1	15
66	A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 293.	1.6	14
67	Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. <i>Annals of Oncology</i> , 2021, 32, 58-65.	1.2	14
68	Risk estimations and treatment decisions in early stage breast cancer: Agreement among oncologists and the impact of the 70-gene signature. <i>European Journal of Cancer</i> , 2014, 50, 1045-1054.	2.8	13
69	Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1867-1869.	1.6	13
70	Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study. <i>Genetics in Medicine</i> , 2016, 18, 720-726.	2.4	13
71	(Very) Early technology assessment and translation of predictive biomarkers in breast cancer. <i>Cancer Treatment Reviews</i> , 2017, 52, 117-127.	7.7	13
72	Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial. <i>Contemporary Clinical Trials</i> , 2017, 61, 96-100.	1.8	13

#	ARTICLE	IF	CITATIONS
73	Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study. <i>European Journal of Cancer</i> , 2018, 90, 92-101.	2.8	13
74	Neoadjuvant tamoxifen synchronizes ER \pm binding and gene expression profiles related to outcome and proliferation. <i>Oncotarget</i> , 2016, 7, 33901-33918.	1.8	13
75	Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. <i>Human Reproduction</i> , 2022, 37, 1786-1794.	0.9	13
76	Simultaneous analysis of E1 and E2 by LC-MS/MS in healthy volunteers: estimation of reference intervals and comparison with a conventional E2 immunoassay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1178, 122563.	2.3	12
77	Long-term prognosis of young breast cancer patients (≥ 40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. <i>BMJ Open</i> , 2017, 7, e017842.	1.9	11
78	Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 1401-1409.	6.4	11
79	Copy number profiling by array comparative genomic hybridization identifies frequently occurring <i>BRCA1</i> -like male breast cancer. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 734-744.	2.8	10
80	Lack of Genomic Heterogeneity at High-Resolution aCGH between Primary Breast Cancers and Their Paired Lymph Node Metastases. <i>PLoS ONE</i> , 2014, 9, e103177.	2.5	9
81	Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). <i>European Journal of Cancer</i> , 2018, 102, 40-48.	2.8	9
82	Ovarian Cancer-Specific <i>BRCA1</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	7.0	9
83	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. <i>International Journal of Cancer</i> , 2019, 145, 1325-1333.	5.1	8
84	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 113531-113542.	1.8	8
85	A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial. <i>Cancer</i> , 2016, 122, 2961-2970.	4.1	7
86	Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot. <i>BMC Cancer</i> , 2018, 18, 761.	2.6	7
87	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. <i>International Journal of Cancer</i> , 2019, 145, 274-283.	5.1	7
88	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. <i>Apmis</i> , 2020, 128, 298-307.	2.0	7
89	Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1506-1514.	6.3	6
90	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.	1.6	6

#	ARTICLE	IF	CITATIONS
91	St. Gallen endocrine response classes predict recurrence rates over time. <i>Breast</i> , 2015, 24, 705-712.	2.2	5
92	A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer. <i>International Journal of Cancer</i> , 2021, 148, 3041-3050.	5.1	5
93	Molecular Profiling Is Rather Likely to Be Cost Effective. <i>Journal of Clinical Oncology</i> , 2015, 33, 1626-1627.	1.6	4
94	Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 149-163.	2.5	4
95	Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 675-685.	2.5	4
96	Pregnancy-associated breast cancer: the influence of gestational age. <i>Endocrine-Related Cancer</i> , 2022, 29, 129-138.	3.1	4
97	FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer. <i>Cell Reports</i> , 2022, 39, 110584.	6.4	4
98	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	7.0	4
99	Gene expression profiling in breast cancer - design of a pooled database to address open questions. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2009, 41, 221-227.	0.7	3
100	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). <i>Breast Care</i> , 2021, 16, 1-9.	1.4	3
101	BRCA-like classification in ovarian cancer: Results from the AGO-TR1-trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 5546-5546.	1.6	3
102	Adjuvant chemotherapy in small node-negative triple-negative breast cancer (TNBC). <i>Journal of Clinical Oncology</i> , 2019, 37, 536-536.	1.6	3
103	Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?. <i>Cureus</i> , 2015, 7, e433.	0.5	3
104	Treating the genetic make-up of breast cancer: a new fashion?. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1065-1067.	2.4	2
105	BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 775-785.	2.5	2
106	Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 817-830.	2.5	2
107	Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. <i>Journal of Clinical Oncology</i> , 2009, 27, 587-587.	1.6	2
108	Optimal endocrine therapy for breast cancer patients 45-50 years of age at diagnosis. <i>Journal of Clinical Oncology</i> , 2016, 34, 551-551.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. <i>Breast Cancer Research and Treatment</i> , 2022, , .	2.5	2
110	The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care. <i>Cancer Informatics</i> , 2016, 15, CIN.S38122.	1.9	1
111	Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04). <i>European Journal of Surgical Oncology</i> , 2017, 43, 619-624.	1.0	1
112	Anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.. <i>Journal of Clinical Oncology</i> , 2017, 35, 523-523.	1.6	1
113	IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women. <i>Npj Breast Cancer</i> , 2021, 7, 138.	5.2	1
114	Immune landscape of breast tumors with low and intermediate estrogen receptor (ER) expression.. <i>Journal of Clinical Oncology</i> , 2022, 40, 566-566.	1.6	1
115	Response to Klar and Adams. <i>Journal of the National Cancer Institute</i> , 2022, 114, 167-168.	6.3	0
116	Predictive value of ectopic <i>HORMAD1</i> tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 541-541.	1.6	0